Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 252

1.

Impact of the Duration of Diabetes Mellitus on the Outcome of Metastatic Pancreatic Cancer Treated with Gemcitabine: A Retrospective Study.

Iizumi S, Kuchiba A, Okusaka T, Ikeda M, Sakamoto Y, Kondo S, Morizane C, Ueno H, Osame K, Mitsunaga S, Ohno I, Imaoka H, Hashimoto Y, Takahashi H, Sasaki M, Ohashi K.

Intern Med. 2019 Jun 7. doi: 10.2169/internalmedicine.2539-18. [Epub ahead of print]

2.

Effect of hyperuricemia and treatment for hyperuricemia in Japanese hemodialysis patients: A cohort study.

Sugano N, Maruyama Y, Kidoguchi S, Ohno I, Wada A, Shigematsu T, Masakane I, Yokoo T.

PLoS One. 2019 Jun 6;14(6):e0217859. doi: 10.1371/journal.pone.0217859. eCollection 2019.

3.

Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study.

Ueno M, Ikeda M, Morizane C, Kobayashi S, Ohno I, Kondo S, Okano N, Kimura K, Asada S, Namba Y, Okusaka T, Furuse J.

Lancet Gastroenterol Hepatol. 2019 May 17. pii: S2468-1253(19)30086-X. doi: 10.1016/S2468-1253(19)30086-X. [Epub ahead of print]

PMID:
31109808
4.

First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors.

Shimomura A, Yamamoto N, Kondo S, Fujiwara Y, Suzuki S, Yanagitani N, Horiike A, Kitazono S, Ohyanagi F, Doi T, Kuboki Y, Kawazoe A, Shitara K, Ohno I, Banerji U, Sundar R, Ohkubo S, Calleja EM, Nishio M.

Mol Cancer Ther. 2019 Mar;18(3):531-540. doi: 10.1158/1535-7163.MCT-18-0831. Epub 2019 Jan 24.

PMID:
30679388
5.

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, Assenat E, Brandi G, Pracht M, Lim HY, Rau KM, Motomura K, Ohno I, Merle P, Daniele B, Shin DB, Gerken G, Borg C, Hiriart JB, Okusaka T, Morimoto M, Hsu Y, Abada PB, Kudo M; REACH-2 study investigators.

Lancet Oncol. 2019 Feb;20(2):282-296. doi: 10.1016/S1470-2045(18)30937-9. Epub 2019 Jan 18.

PMID:
30665869
6.

Endoscopic Ultrasound-Guided Gallbladder Drainage for Aberrant Right Posterior Duct Obstruction Developing after Placement of a Covered Self-Expandable Metallic Stent in a Patient with Distal Biliary Obstruction.

Suzuki Y, Hashimoto Y, Shibuki T, Kan M, Kimura G, Umemoto K, Watanabe K, Sasaki M, Takahashi H, Imaoka H, Ohno I, Mitsunaga S, Ikeda M.

Case Rep Gastroenterol. 2018 Nov 28;12(3):722-728. doi: 10.1159/000492215. eCollection 2018 Sep-Dec.

7.

Maternal Separation as Early-Life Stress Causes Enhanced Allergic Airway Responses by Inhibiting Respiratory Tolerance in Mice.

Ouchi R, Kawano T, Yoshida H, Ishii M, Miyasaka T, Ohkawara Y, Takayanagi M, Takahashi T, Ohno I.

Tohoku J Exp Med. 2018 Nov;246(3):155-165. doi: 10.1620/tjem.246.155.

8.

Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy.

Suzuki Y, Kan M, Kimura G, Umemoto K, Watanabe K, Sasaki M, Takahashi H, Hashimoto Y, Imaoka H, Ohno I, Mitsunaga S, Ikeda M.

J Gastroenterol. 2019 Mar;54(3):281-290. doi: 10.1007/s00535-018-1518-3. Epub 2018 Oct 8.

9.

Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial.

Kimura K, Hosoya T, Uchida S, Inaba M, Makino H, Maruyama S, Ito S, Yamamoto T, Tomino Y, Ohno I, Shibagaki Y, Iimuro S, Imai N, Kuwabara M, Hayakawa H, Ohtsu H, Ohashi Y; FEATHER Study Investigators.

Am J Kidney Dis. 2018 Dec;72(6):798-810. doi: 10.1053/j.ajkd.2018.06.028. Epub 2018 Sep 1.

10.

Alternate Endpoints for Phase II Trials in Advanced Neuroendocrine Tumors.

Imaoka H, Sasaki M, Takahashi H, Hashimoto Y, Ohno I, Mitsunaga S, Watanabe K, Umemoto K, Kimura G, Suzuki Y, Kan M, Ikeda M.

Oncologist. 2019 Jan;24(1):47-53. doi: 10.1634/theoncologist.2017-0651. Epub 2018 Aug 2. Review.

PMID:
30072388
11.

Phase I study of resminostat, an HDAC inhibitor, combined with S-1 in patients with pre-treated biliary tract or pancreatic cancer.

Ikeda M, Ohno I, Ueno H, Mitsunaga S, Hashimoto Y, Okusaka T, Kondo S, Sasaki M, Sakamoto Y, Takahashi H, Hara R, Kobayashi S, Nakamura O, Morizane C.

Invest New Drugs. 2019 Feb;37(1):109-117. doi: 10.1007/s10637-018-0634-5. Epub 2018 Jul 11.

PMID:
29995287
12.

Increased Susceptibility to Allergic Asthma with the Impairment of Respiratory Tolerance Caused by Psychological Stress.

Kawano T, Ouchi R, Ishigaki T, Masuda C, Miyasaka T, Ohkawara Y, Ohta N, Takayanagi M, Takahashi T, Ohno I.

Int Arch Allergy Immunol. 2018;177(1):1-15. doi: 10.1159/000488289. Epub 2018 Jun 6.

PMID:
29874662
13.

Characterization of low active ghrelin ratio in patients with advanced pancreatic cancer.

Miura T, Mitsunaga S, Ikeda M, Ohno I, Takahashi H, Suzuki H, Irisawa A, Kuwata T, Ochiai A.

Support Care Cancer. 2018 Nov;26(11):3811-3817. doi: 10.1007/s00520-018-4248-4. Epub 2018 May 18.

PMID:
29777378
14.

Biology of GM3 Ganglioside.

Inokuchi JI, Inamori KI, Kabayama K, Nagafuku M, Uemura S, Go S, Suzuki A, Ohno I, Kanoh H, Shishido F.

Prog Mol Biol Transl Sci. 2018;156:151-195. doi: 10.1016/bs.pmbts.2017.10.004. Epub 2018 Feb 3. Review.

PMID:
29747813
15.

Neural Invasion Spreads Macrophage-Related Allodynia via Neural Root in Pancreatic Cancer.

Miura T, Mitsunaga S, Ikeda M, Ohno I, Takahashi H, Kuwata T, Ochiai A.

Anesth Analg. 2018 May;126(5):1729-1738. doi: 10.1213/ANE.0000000000002803.

PMID:
29570153
16.

EUS-guided n-butyl-2-cyanoacrylate injection therapy for ruptured isolated left gastric artery pseudoaneurysm.

Hashimoto Y, Ohno I, Takahashi H, Sasaki M, Imaoka H, Watanabe K, Umemoto K, Kimura G, Mitsunaga S, Ikeda M.

Endosc Ultrasound. 2019 Jan-Feb;8(1):58-59. doi: 10.4103/eus.eus_109_17. No abstract available.

17.

Sex-based differences in CD103+ dendritic cells promote female-predominant Th2 cytokine production during allergic asthma.

Masuda C, Miyasaka T, Kawakami K, Inokuchi J, Kawano T, Dobashi-Okuyama K, Takahashi T, Takayanagi M, Ohno I.

Clin Exp Allergy. 2018 Apr;48(4):379-393. doi: 10.1111/cea.13081. Epub 2018 Feb 2.

PMID:
29288569
18.

ETosis-derived DNA trap production in middle ear effusion is a common feature of eosinophilic otitis media.

Ohta N, Ueki S, Konno Y, Hirokawa M, Kubota T, Tomioka-Matsutani S, Suzuki T, Ishida Y, Kawano T, Miyasaka T, Takahashi T, Suzuki T, Ohno I, Kakehata S, Fujieda S.

Allergol Int. 2018 Jul;67(3):414-416. doi: 10.1016/j.alit.2017.11.007. Epub 2017 Dec 11. No abstract available.

19.

Neoadjuvant S-1 with concurrent radiotherapy followed by surgery for borderline resectable pancreatic cancer: study protocol for an open-label, multicentre, prospective phase II trial (JASPAC05).

Takahashi S, Ohno I, Ikeda M, Kobayashi T, Akimoto T, Kojima M, Konishi M, Uesaka K.

BMJ Open. 2017 Oct 22;7(10):e018445. doi: 10.1136/bmjopen-2017-018445.

20.

Flupyrimin: A Novel Insecticide Acting at the Nicotinic Acetylcholine Receptors.

Onozaki Y, Horikoshi R, Ohno I, Kitsuda S, Durkin KA, Suzuki T, Asahara C, Hiroki N, Komabashiri R, Shimizu R, Furutani S, Ihara M, Matsuda K, Mitomi M, Kagabu S, Uomoto K, Tomizawa M.

J Agric Food Chem. 2017 Sep 13;65(36):7865-7873. doi: 10.1021/acs.jafc.7b02924. Epub 2017 Aug 28.

PMID:
28820587
21.

Progression-free survival as a surrogate endpoint in advanced neuroendocrine neoplasms.

Imaoka H, Sasaki M, Takahashi H, Hashimoto Y, Ohno I, Mitsunaga S, Watanabe K, Umemoto K, Kimura G, Suzuki Y, Ikeda M.

Endocr Relat Cancer. 2017 Sep;24(9):475-483. doi: 10.1530/ERC-17-0197. Epub 2017 Jul 6.

PMID:
28684542
22.
23.

The interplay between neuroendocrine activity and psychological stress-induced exacerbation of allergic asthma.

Miyasaka T, Dobashi-Okuyama K, Takahashi T, Takayanagi M, Ohno I.

Allergol Int. 2018 Jan;67(1):32-42. doi: 10.1016/j.alit.2017.04.013. Epub 2017 May 20. Review.

24.

THE INTERRELATIONSHIP BETWEEN ASTHMA AND BRAIN ACTIVITIES: PSYCHOLOGICAL STRESS-RELATED ASTHMA AS A NEW ASTHMA PHENOTYPE.

Ohno I.

Arerugi. 2017;66(3):153-160. doi: 10.15036/arerugi.66.153. Japanese. No abstract available.

PMID:
28515395
25.

Transarterial (Chemo)Embolization for Liver Metastases in Patients with Neuroendocrine Tumors.

Okuyama H, Ikeda M, Takahashi H, Ohno I, Hashimoto Y, Mitsunaga S, Sakamoto Y, Kondo S, Morizane C, Ueno H, Kobayashi T, Arai Y, Okusaka T.

Oncology. 2017;92(6):353-359. doi: 10.1159/000463388. Epub 2017 Mar 23.

PMID:
28329738
26.

Phase I trial of GBS-01 for advanced pancreatic cancer refractory to gemcitabine.

Ikeda M, Sato A, Mochizuki N, Toyosaki K, Miyoshi C, Fujioka R, Mitsunaga S, Ohno I, Hashimoto Y, Takahashi H, Hasegawa H, Nomura S, Takahashi R, Yomoda S, Tsuchihara K, Kishino S, Esumi H.

Cancer Sci. 2016 Dec;107(12):1818-1824. doi: 10.1111/cas.13086. Epub 2016 Dec 19.

27.

The involvement of central nervous system histamine receptors in psychological stress-induced exacerbation of allergic airway inflammation in mice.

Miyasaka T, Okuyama-Dobashi K, Masuda C, Iwami S, Sato M, Mizoguchi H, Kawano T, Ohkawara Y, Sakurada S, Takayanagi M, Ohno I.

Allergol Int. 2016 Sep;65 Suppl:S38-44. doi: 10.1016/j.alit.2016.05.015. Epub 2016 Aug 11.

28.

An Attempt to Measure Presentation Skill Acquisition Using Peer and Self-evaluation.

Morone M, Sato A, Ohno I, Ohkawara Y, Suzuki T, Nakamura H, Azuma Y.

Yakugaku Zasshi. 2016;136(7):1041-9. doi: 10.1248/yakushi.15-00239. Japanese.

29.

“New continuous tracheal suction technique” used for patients with severe physical and mental disabilities or intractable neurological disease.

Wakisaka A, Nakamura N, Tsuji T, Yamada S, Maruhashi K, Ohno I, Seki H.

No To Hattatsu. 2016 Jul;48(4):288-90. Japanese. No abstract available.

PMID:
30011144
30.

Screening rate for hepatitis B virus infection in patients undergoing chemotherapy in Japan.

Ikeda M, Yamamoto H, Kaneko M, Oshima H, Takahashi H, Umemoto K, Watanabe K, Hashimoto Y, Ohno I, Mitsunaga S, Okusaka T.

Int J Clin Oncol. 2016 Dec;21(6):1162-1166. Epub 2016 Jun 3.

PMID:
27260010
31.

Reduction of proteinuria by therapeutic intervention improves the renal outcome of elderly patients with IgA nephropathy.

Okabayashi Y, Tsuboi N, Haruhara K, Kanzaki G, Koike K, Shimizu A, Miyazaki Y, Ohno I, Kawamura T, Ogura M, Yokoo T.

Clin Exp Nephrol. 2016 Dec;20(6):910-917. doi: 10.1007/s10157-016-1239-y. Epub 2016 Feb 1.

PMID:
26830548
32.

How do case presentation teaching methods affect learning outcomes?--SNAPPS and the One-Minute preceptor.

Seki M, Otaki J, Breugelmans R, Komoda T, Nagata-Kobayashi S, Akaishi Y, Hiramoto J, Ohno I, Harada Y, Hirayama Y, Izumi M.

BMC Med Educ. 2016 Jan 13;16:12. doi: 10.1186/s12909-016-0531-6.

33.

Phase I clinical trial of oral administration of S-1 in combination with intravenous gemcitabine and cisplatin in patients with advanced biliary tract cancer.

Shoji H, Morizane C, Sakamoto Y, Kondo S, Ueno H, Takahashi H, Ohno I, Shimizu S, Mitsunaga S, Ikeda M, Okusaka T.

Jpn J Clin Oncol. 2016 Feb;46(2):132-7. doi: 10.1093/jjco/hyv179. Epub 2015 Dec 18.

PMID:
26685318
34.

Systemic Chemotherapy for Advanced Hepatocellular Carcinoma: Past, Present, and Future.

Ikeda M, Mitsunaga S, Ohno I, Hashimoto Y, Takahashi H, Watanabe K, Umemoto K, Okusaka T.

Diseases. 2015 Dec 1;3(4):360-381. doi: 10.3390/diseases3040360. Review.

35.
36.

C-Reactive Protein Level Is an Indicator of the Aggressiveness of Advanced Pancreatic Cancer.

Mitsunaga S, Ikeda M, Shimizu S, Ohno I, Takahashi H, Okuyama H, Ueno H, Morizane C, Kondo S, Sakamoto Y, Okusaka T, Ochiai A.

Pancreas. 2016 Jan;45(1):110-6. doi: 10.1097/MPA.0000000000000465.

PMID:
26566216
37.

Zoledronate Therapy for the Pathological Humeral Fracture in Polyostotic Fibrous Dysplasia: A Case Report.

Ohno I, Higuchi C.

J Clin Med Res. 2015 Nov;7(11):901-6. doi: 10.14740/jocmr2318w. Epub 2015 Sep 25.

38.

CD8+ T Cells Mediate Female-Dominant IL-4 Production and Airway Inflammation in Allergic Asthma.

Ito C, Okuyama-Dobashi K, Miyasaka T, Masuda C, Sato M, Kawano T, Ohkawara Y, Kikuchi T, Takayanagi M, Ohno I.

PLoS One. 2015 Oct 21;10(10):e0140808. doi: 10.1371/journal.pone.0140808. eCollection 2015.

39.

Cytotoxic chemotherapy for pancreatic neuroendocrine tumors.

Okusaka T, Ueno H, Morizane C, Kondo S, Sakamoto Y, Takahashi H, Ohno I, Shimizu S, Mitsunaga S, Ikeda M.

J Hepatobiliary Pancreat Sci. 2015 Aug;22(8):628-33. doi: 10.1002/jhbp.257. Epub 2015 May 3. Review.

PMID:
25940377
40.

Characterization of patients with advanced pancreatic cancer and high serum interleukin-6 levels.

Miura T, Mitsunaga S, Ikeda M, Shimizu S, Ohno I, Takahashi H, Furuse J, Inagaki M, Higashi S, Kato H, Terao K, Ochiai A.

Pancreas. 2015 Jul;44(5):756-63. doi: 10.1097/MPA.0000000000000335.

PMID:
25931255
41.

[A three-week regimen of S-1 monotherapy reduced gastrointestinal toxicity and maintained efficacy in patients with gemcitabine-refractory advanced pancreatic cancer].

Tanaka H, Mitsunaga S, Kobayashi M, Funazaki H, Katayama S, Kuwahara A, Okuyama H, Takahashi H, Ohno I, Shimizu S, Sakamoto Y, Kondo S, Morizane C, Ueno H, Okusaka T, Ochiai A, Ikeda M.

Gan To Kagaku Ryoho. 2015 Mar;42(3):313-7. Japanese.

PMID:
25812499
42.

Chemotherapy for advanced poorly differentiated pancreatic neuroendocrine carcinoma.

Ikeda M, Okuyama H, Takahashi H, Ohno I, Shimizu S, Mitsunaga S, Kondo S, Morizane C, Ueno H, Okusaka T.

J Hepatobiliary Pancreat Sci. 2015 Aug;22(8):623-7. doi: 10.1002/jhbp.228. Epub 2015 Mar 5. Review.

PMID:
25755102
43.

Efficacy of prophylactic minocycline treatment for skin toxicities induced by erlotinib plus gemcitabine in patients with advanced pancreatic cancer: a retrospective study.

Shinohara A, Ikeda M, Okuyama H, Kobayashi M, Funazaki H, Mitsunaga S, Shimizu S, Ohno I, Takahashi H, Ichida Y, Takahashi K, Okusaka T, Saitoh S.

Am J Clin Dermatol. 2015 Jun;16(3):221-9. doi: 10.1007/s40257-015-0116-x.

PMID:
25687689
44.

[Relationship between serum uric acid levels and muscle strength/volume: a new insight from a large-scale survey].

Kuriyama S, Nakano T, Maruyama Y, Sugano N, Takane K, Suetsugu Y, Takahashi Y, Kobayashi C, Nishio S, Takahashi D, Kidoguchi S, Ichida K, Ohno I, Hosoya T, Yokoo T.

Nihon Jinzo Gakkai Shi. 2014;56(8):1260-9. Japanese.

PMID:
25551987
45.

Prognostic factors in patients with hepatocellular carcinoma refractory or intolerant to sorafenib.

Okuyama H, Ikeda M, Kuwahara A, Takahashi H, Ohno I, Shimizu S, Mitsunaga S, Senda S, Okusaka T.

Oncology. 2015;88(4):241-6. doi: 10.1159/000369351. Epub 2014 Dec 11.

PMID:
25503567
46.

Distinct selectivity of gangliosides required for CD4⁺ T and CD8⁺ T cell activation.

Inokuchi J, Nagafuku M, Ohno I, Suzuki A.

Biochim Biophys Acta. 2015 Jan;1851(1):98-106. doi: 10.1016/j.bbalip.2014.07.013. Epub 2014 Sep 3. Review.

PMID:
25193136
47.

Safety, efficacy and renal effect of febuxostat in patients with moderate-to-severe kidney dysfunction.

Shibagaki Y, Ohno I, Hosoya T, Kimura K.

Hypertens Res. 2014 Oct;37(10):919-25. doi: 10.1038/hr.2014.107. Epub 2014 Jun 19.

PMID:
24942770
48.

The involvement of glucocorticoids in psychological stress-induced exacerbations of experimental allergic asthma.

Okuyama K, Dobashi K, Miyasaka T, Yamazaki N, Kikuchi T, Sora I, Takayanagi M, Kita H, Ohno I.

Int Arch Allergy Immunol. 2014;163(4):297-306. doi: 10.1159/000360577. Epub 2014 Apr 26.

PMID:
24776388
49.

Mucosal gene therapy using a pseudotyped lentivirus vector encoding murine interleukin-10 (mIL-10) suppresses the development and relapse of experimental murine colitis.

Matsumoto H, Haga K, Ohno I, Hiraoka K, Kimura T, Hermann K, Kasahara N, Anton P, McGowan I.

BMC Gastroenterol. 2014 Apr 8;14:68. doi: 10.1186/1471-230X-14-68.

50.

[Liver cancer: progress in diagnosis and treatments. Topics: VI. Progress in treatments of liver cancer; 4. Molecularly targeted agent].

Ikeda M, Mitsunaga S, Shimizu S, Ohno I, Takahashi H, Okuyama H, Kuwahara A, Okusaka T.

Nihon Naika Gakkai Zasshi. 2014 Jan 10;103(1):93-101. Japanese. No abstract available.

PMID:
24605496

Supplemental Content

Support Center